Sonnet Biotherapeutc Hldng Inc Financials
Sonnet Biotherapeutc Hldng Inc (SONN) reported $1.0M in revenue for fiscal year 2025, up 5268.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 was a balance-sheet reset funded externally, while the core business still operated as a cash-burning development program.
From FY2024 to FY2025, solvency improved because capital was raised, not because operations turned. A$26.0M financing inflow lifted cash to$5.1M even as both net loss and operating cash flow stayed deeply negative, so the healthier current ratio reflects recapitalization more than self-funding.
Even with FY2025 revenue at
Losses were also fairly cash-real: FY2025 net loss of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sonnet Biotherapeutc Hldng Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sonnet Biotherapeutc Hldng Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
Not available for Sonnet Biotherapeutc Hldng Inc, and counted as zero in the overall score.
Sonnet Biotherapeutc Hldng Inc has a moderate D/E ratio of 0.38. This balance of debt and equity financing earns a leverage score of 64/100.
With a current ratio of 3.50, Sonnet Biotherapeutc Hldng Inc holds $3.50 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 82/100.
Not available for Sonnet Biotherapeutc Hldng Inc, and counted as zero in the overall score.
Sonnet Biotherapeutc Hldng Inc posts a -148.4% return on equity (ROE), meaning it loses $148 for every $100 of shareholders' equity. This results in a returns score of 3/100.
Sonnet Biotherapeutc Hldng Inc scores -11.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($27.0M) relative to total liabilities ($4.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sonnet Biotherapeutc Hldng Inc passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Sonnet Biotherapeutc Hldng Inc reported a net loss of $16.0M while operations used $12.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Sonnet Biotherapeutc Hldng Inc generated $1.0M in revenue in fiscal year 2025. This represents an increase of 5268.8% from the prior year.
Sonnet Biotherapeutc Hldng Inc's EBITDA was -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 33.8% from the prior year.
Sonnet Biotherapeutc Hldng Inc reported -$16.0M in net income in fiscal year 2025. This represents a decrease of 115.3% from the prior year.
Sonnet Biotherapeutc Hldng Inc earned -$3.95 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
Sonnet Biotherapeutc Hldng Inc held $5.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Sonnet Biotherapeutc Hldng Inc's ROE was -148.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Sonnet Biotherapeutc Hldng Inc invested $8.4M in research and development in fiscal year 2025. This represents an increase of 45.6% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
SONN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M+5268.8% | $19K-87.4% | $148K-57.8% | $350K-27.6% | $484K | N/A | $30.1M-25.8% | $40.6M-2.0% | $41.4M-0.6% | $41.7M+18.0% | $35.4M+18.5% | $29.8M+261.8% | $8.2M+20.4% | $6.9M+364.0% | $1.5M |
| R&D Expenses | $8.4M+45.6% | $5.7M-51.4% | $11.8M-44.9% | $21.4M+28.9% | $16.6M+68.4% | $9.9M+349.1% | $2.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $8.5M+38.5% | $6.1M-14.0% | $7.1M-16.9% | $8.6M-4.0% | $8.9M+18.6% | $7.5M+26.3% | $6.0M+54.5% | $3.9M-15.0% | $4.5M-21.6% | $5.8M-14.7% | $6.8M+13.7% | $6.0M+41.2% | $4.2M+83.3% | $2.3M+84.8% | $1.2M |
| Operating Income | -$15.8M-33.7% | -$11.8M+36.9% | -$18.8M | N/A | -$25.1M-3.5% | -$24.2M-50.7% | -$16.1M-199.4% | -$5.4M-2.6% | -$5.2M-99.8% | -$2.6M+48.4% | -$5.1M+8.4% | -$5.5M-20.4% | -$4.6M-77.7% | -$2.6M-171.1% | -$956K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $21K-96.9% | $674K-73.6% | $2.5M-1.7% | $2.6M+10.5% | $2.3M-32.3% | $3.5M+52.0% | $2.3M+201.0% | $758K+59.5% | $475K+158.9% | $183K |
| Income Tax | $218K | N/A | N/A | N/A | N/A | N/A | $74K+110.5% | -$701K-8.8% | -$644K-424.7% | $198K+5.8% | $188K+139.4% | -$477K-1264.0% | $41K+113.1% | $19K | $0 |
| Net Income | -$16.0M-115.3% | -$7.4M+60.5% | -$18.8M | N/A | -$25.0M-3.0% | -$24.3M-36.9% | -$17.7M-158.6% | -$6.9M-0.9% | -$6.8M+25.1% | -$9.1M+25.2% | -$12.1M-89.5% | -$6.4M-22.8% | -$5.2M-64.7% | -$3.2M-172.3% | -$1.2M |
| EPS (Diluted) | -$3.95 | -$11.35 | -$145.13+3.6% | -$150.52 | N/A | N/A | N/A | N/A | N/A | N/A | $0.00 | -$0.15 | -$0.01 | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
SONN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $14.9M+437.1% | $2.8M-49.0% | $5.4M-6.9% | $5.8M-79.9% | $29.0M+262.7% | $8.0M-74.6% | $31.5M+5.8% | $29.8M-1.3% | $30.2M-9.9% | $33.5M-20.7% | $42.2M+17.9% | $35.8M+78.2% | $20.1M+162.7% | $7.6M+59.3% | $4.8M |
| Current Assets | $14.3M+577.2% | $2.1M-55.3% | $4.7M-12.5% | $5.4M-81.2% | $28.8M+277.2% | $7.6M+553.0% | $1.2M-13.0% | $1.3M-25.3% | $1.8M+0.3% | $1.8M-53.0% | $3.8M+160.0% | $1.5M-14.3% | $1.7M-15.6% | $2.0M+216.3% | $642K |
| Cash & Equivalents | $5.1M+3325.9% | $149K-93.4% | $2.3M-25.5% | $3.1M-88.9% | $27.6M+275.8% | $7.3M+1368.0% | $501K-20.6% | $630K+43.7% | $438K+63.3% | $269K-82.4% | $1.5M+521.5% | $246K-44.5% | $443K-63.8% | $1.2M+641.1% | $165K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | $287K-14.3% | $335K-27.2% | $461K-14.6% | $540K-5.3% | $570K+6.9% | $533K+39.7% | $381K+68.0% | $227K+116.1% | $105K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $387K-18.6% | $476K-9.2% | $524K-39.2% | $863K+175.3% | $314K+38.0% | $227K+41.0% | $161K+48.2% | $109K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $8.6M-18.9% | $10.6M-16.5% | $12.6M+2.0% | $12.4M-2.3% | $12.7M+52.6% | $8.3M+28.2% | $6.5M+1538.6% | $396K0.0% | $396K |
| Total Liabilities | $4.1M+25.8% | $3.3M-42.4% | $5.7M-32.4% | $8.4M+24.3% | $6.7M+35.4% | $5.0M-85.7% | $34.7M+61.1% | $21.5M+15.2% | $18.7M-5.5% | $19.8M-3.3% | $20.4M-1.8% | $20.8M+135.3% | $8.8M+317.8% | $2.1M-50.9% | $4.3M |
| Current Liabilities | $4.1M+27.6% | $3.2M-41.9% | $5.5M-32.3% | $8.2M+21.8% | $6.7M+41.9% | $4.7M-73.9% | $18.1M+38.9% | $13.0M-11.6% | $14.7M+23.4% | $11.9M-26.2% | $16.2M+41.8% | $11.4M+106.3% | $5.5M+212.0% | $1.8M-52.3% | $3.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $6.6M+121.0% | $3.0M-47.8% | $5.7M+1897.6% | $287K-73.8% | $1.1M-78.1% | $5.0M+1155.8% | $399K | $0-100.0% | $236K |
| Total Equity | $10.8M+2320.9% | -$486K-114.9% | -$226K+91.1% | -$2.5M-111.4% | $22.3M+637.1% | $3.0M+225.9% | -$2.4M-132.3% | $7.4M-30.6% | $10.7M-14.8% | $12.6M-41.2% | $21.4M+42.7% | $15.0M+33.2% | $11.2M+103.3% | $5.5M+1038.1% | $486K |
| Retained Earnings | -$133.7M-13.6% | -$117.7M-6.7% | -$110.2M-20.6% | -$91.4M-48.2% | -$61.7M-68.1% | -$36.7M+51.1% | -$75.1M-31.4% | -$57.1M-16.3% | -$49.1M-16.4% | -$42.2M-27.8% | -$33.0M-58.1% | -$20.9M-44.2% | -$14.5M-56.3% | -$9.3M-52.0% | -$6.1M |
SONN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.8M-49.0% | -$8.6M+59.7% | -$21.3M+23.2% | -$27.8M-23.2% | -$22.6M-44.4% | -$15.6M-285.9% | -$4.0M-264.7% | -$1.1M-53.2% | -$724K-42.3% | -$509K+90.3% | -$5.3M-411.3% | -$1.0M+62.0% | -$2.7M-13.7% | -$2.4M-105.6% | -$1.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | $4K-95.2% | $76K-83.9% | $473K-72.2% | $1.7M+4.5% | $1.6M+36.5% | $1.2M-33.8% | $1.8M-8.7% | $2.0M-46.1% | $3.7M+211.7% | $1.2M+434.0% | $220K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$22.6M-43.8% | -$15.7M-247.2% | -$4.5M-60.9% | -$2.8M-19.5% | -$2.3M-38.2% | -$1.7M+75.9% | -$7.0M-135.2% | -$3.0M+52.9% | -$6.4M-79.1% | -$3.6M-158.1% | -$1.4M |
| Investing Cash Flow | -$12K0.0% | -$12K+97.3% | -$443K+45.3% | -$810K-22263.4% | -$4K+95.2% | -$76K-111.2% | $679K+133.1% | -$2.1M-76.2% | -$1.2M | N/A | N/A | -$2.2M+46.6% | -$4.1M-55.4% | -$2.6M-66.4% | -$1.6M |
| Financing Cash Flow | $26.0M+301.0% | $6.5M-69.1% | $21.0M+423.3% | $4.0M-90.6% | $42.8M+86.2% | $23.0M+588.1% | $3.3M+58.0% | $2.1M+1.6% | $2.1M | N/A | N/A | $3.0M-48.6% | $5.9M-2.2% | $6.0M+111.2% | $2.9M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$500 |
Not reported in any period shown, so not listed: Dividends Paid.
SONN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1584.4% | -63617.9% | -12714.5% | N/A | -5187.4% | N/A | -53.3%-40.1pp | -13.2%-0.6pp | -12.6%-6.4pp | -6.3%+8.1pp | -14.4%+4.2pp | -18.6%+37.3pp | -55.9%-18.0pp | -37.8%+26.9pp | -64.7% |
| Net Margin | -1601.2% | -39929.3% | -12741.6% | N/A | -5166.0% | N/A | -58.8%-41.9pp | -16.9%-0.5pp | -16.4%+5.4pp | -21.8%+12.6pp | -34.3%-12.9pp | -21.5%+41.8pp | -63.2%-17.0pp | -46.2%+32.5pp | -78.7% |
| Return on Equity | -148.4% | N/A | N/A | N/A | -112.2%+691.3pp | -803.5% | N/A | -92.3%-28.8pp | -63.5%+8.8pp | -72.2%-15.4pp | -56.8%-14.0pp | -42.8%+3.6pp | -46.4%+10.9pp | -57.3%+182.1pp | -239.4% |
| Return on Assets | -107.6%+160.8pp | -268.4%+78.5pp | -346.9% | N/A | -86.2%+217.4pp | -303.5%-247.3pp | -56.2%-33.2pp | -23.0%-0.5pp | -22.5%+4.6pp | -27.1%+1.7pp | -28.8%-10.9pp | -17.9%+8.1pp | -26.0%+15.5pp | -41.4%-17.2pp | -24.2% |
| Current Ratio | 3.50+2.8x | 0.66-0.2x | 0.86+0.2x | 0.66-3.6x | 4.30+2.7x | 1.62+1.6x | 0.060.0x | 0.100.0x | 0.120.0x | 0.15-0.1x | 0.24+0.1x | 0.13-0.2x | 0.31-0.8x | 1.15+1.0x | 0.17 |
| Debt-to-Equity | 0.38 | N/A | N/A | N/A | 0.30-1.3x | 1.65 | N/A | 0.40-0.1x | 0.54+0.5x | 0.020.0x | 0.05-0.3x | 0.33+0.3x | 0.040.0x | 0.00-0.5x | 0.49 |
| FCF Margin | N/A | N/A | N/A | N/A | -4663.9% | N/A | -15.0%-8.1pp | -6.9%-1.2pp | -5.7%-1.6pp | -4.1%+15.9pp | -19.9%-9.9pp | -10.0%+67.1pp | -77.1%-25.3pp | -51.8%+41.4pp | -93.2% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Sonnet Biotherapeutc Hldng Inc Ranks
Frequently Asked Questions
What is Sonnet Biotherapeutc Hldng Inc's annual revenue?
Sonnet Biotherapeutc Hldng Inc (SONN) reported $1.0M in total revenue for fiscal year 2025. This represents a 5268.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sonnet Biotherapeutc Hldng Inc's revenue growing?
Sonnet Biotherapeutc Hldng Inc (SONN) revenue grew by 5268.8% year-over-year, from $19K to $1.0M in fiscal year 2025.
Is Sonnet Biotherapeutc Hldng Inc profitable?
No, Sonnet Biotherapeutc Hldng Inc (SONN) reported a net income of -$16.0M in fiscal year 2025.
What is Sonnet Biotherapeutc Hldng Inc's EBITDA?
Sonnet Biotherapeutc Hldng Inc (SONN) had EBITDA of -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sonnet Biotherapeutc Hldng Inc's return on equity (ROE)?
Sonnet Biotherapeutc Hldng Inc (SONN) has a return on equity of -148.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sonnet Biotherapeutc Hldng Inc's operating cash flow?
Sonnet Biotherapeutc Hldng Inc (SONN) recorded an outflow of $12.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sonnet Biotherapeutc Hldng Inc's total assets?
Sonnet Biotherapeutc Hldng Inc (SONN) had $14.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Sonnet Biotherapeutc Hldng Inc spend on research and development?
Sonnet Biotherapeutc Hldng Inc (SONN) invested $8.4M in research and development during fiscal year 2025.
What is Sonnet Biotherapeutc Hldng Inc's current ratio?
Sonnet Biotherapeutc Hldng Inc (SONN) had a current ratio of 3.50 as of fiscal year 2025, which is generally considered healthy.
What is Sonnet Biotherapeutc Hldng Inc's debt-to-equity ratio?
Sonnet Biotherapeutc Hldng Inc (SONN) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sonnet Biotherapeutc Hldng Inc's return on assets (ROA)?
Sonnet Biotherapeutc Hldng Inc (SONN) had a return on assets of -107.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Sonnet Biotherapeutc Hldng Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Sonnet Biotherapeutc Hldng Inc (SONN) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.8M over that year. Dividing the one by the other, the reported balance equals about 5 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Sonnet Biotherapeutc Hldng Inc's Altman Z-Score?
Sonnet Biotherapeutc Hldng Inc (SONN) has an Altman Z-Score of -11.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sonnet Biotherapeutc Hldng Inc's Piotroski F-Score?
Sonnet Biotherapeutc Hldng Inc (SONN) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sonnet Biotherapeutc Hldng Inc's earnings high quality?
Sonnet Biotherapeutc Hldng Inc (SONN) reported a net loss of $16.0M while operations used $12.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Sonnet Biotherapeutc Hldng Inc?
Sonnet Biotherapeutc Hldng Inc (SONN) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.